Drug–drug interaction study of imatinib and voriconazole in vitro and in vivo

Clicks: 273
ID: 5879
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #995 of 1,693 articles by views in Infection and drug resistance

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,693 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Drug–drug interaction study of imatinib and voriconazole in vitro and in vivo Qianmeng Lin,1,2 Saili Xie,1 Xiangjun Qiu,3 Jingjing Chen,1 Ren-Ai Xu11The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, People’s Republic of China; 2School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325000, People’s Republic of China; 3Medical College of Henan University of Science and Technology, Luoyang 471003, People’s Republic of ChinaBackground: In clinical practice, common problem polypharmacy could result in the increased risks of drug–drug interactions (DDIs). Co-administered imatinib (IMA) and voriconazole (VOR) as one treatment protocol in cancer patients with fungal infections are common.Purpose: The aim of the present study was to assess the potential DDIs associated with the concurrent use of IMA and VOR in rat liver microsomes (RLMs) and in rats.Methods and results: The concentration levels of IMA, VOR, and their metabolites N-desmethyl IMA (CGP74588) and N-oxide voriconazole (N-oxide VOR) were determined by ultra performance liquid chromatography-tandem mass spectrometry. In vitro study of RLMs, VOR inhibited the IMA metabolism with the half-maximal inhibitory concentration (IC50) of 105.20 μM, while IC50 for IMA against VOR was 61.30 μM. After co-administered IMA and VOR in rats, the Cmax of IMA was increased significantly, while the AUC0→t, AUC0→∞, and Cmax of CGP74588 were decreased significantly. In addition, similar results were also found that the main pharmacokinetic parameters (AUC0→t, AUC0→∞, MRT0→∞, Tmax, and Cmax) of VOR were increased significantly, while the AUC0→t, AUC0→∞, and Cmax of N-oxide VOR were decreased significantly. Incorporation of all the results indicated that both drugs had a inhibitory effect on each other’s metabolism in vitro and in vivo.Conclusion: Thus, it is of great value to monitor the concomitant use of IMA and VOR in the clinic to reduce the risks of unexpected clinical outcomes.Keywords: drug–drug interaction, imatinib, voriconazole, rat liver microsome, metabolism
Reference Key
qianmeng2019drugndashdruginfection Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Qianmeng Lin;Saili Xie;Xiangjun Qiu;Jingjing Chen;Ren-Ai Xu and
Journal Infection and drug resistance
Year 2019
DOI
10.2147/IDR.S199526
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.